JP2015532289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532289A5 JP2015532289A5 JP2015534772A JP2015534772A JP2015532289A5 JP 2015532289 A5 JP2015532289 A5 JP 2015532289A5 JP 2015534772 A JP2015534772 A JP 2015534772A JP 2015534772 A JP2015534772 A JP 2015534772A JP 2015532289 A5 JP2015532289 A5 JP 2015532289A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- independently
- cor
- independently selected
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000651 prodrug Substances 0.000 claims description 129
- 229940002612 prodrug Drugs 0.000 claims description 129
- -1 1,2- methylenedioxy Chemical group 0.000 claims description 127
- 229910052736 halogen Inorganic materials 0.000 claims description 123
- 150000002367 halogens Chemical class 0.000 claims description 120
- 125000003118 aryl group Chemical group 0.000 claims description 103
- 125000001931 aliphatic group Chemical group 0.000 claims description 100
- 125000005842 heteroatom Chemical group 0.000 claims description 84
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 83
- 229910052760 oxygen Inorganic materials 0.000 claims description 83
- 229910052717 sulfur Inorganic materials 0.000 claims description 83
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 66
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 66
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 61
- 208000024891 symptom Diseases 0.000 claims description 59
- 230000002757 inflammatory effect Effects 0.000 claims description 52
- 125000004043 oxo group Chemical group O=* 0.000 claims description 47
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 33
- 125000004429 atom Chemical group 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 230000004968 inflammatory condition Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 27
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 16
- 230000036470 plasma concentration Effects 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 102000004388 Interleukin-4 Human genes 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 230000004410 intraocular pressure Effects 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 230000001363 autoimmune Effects 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000018934 joint symptom Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000000552 rheumatic effect Effects 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010060860 Neurological symptom Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 229940125898 compound 5 Drugs 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 25
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 28
- 125000000753 cycloalkyl group Chemical group 0.000 description 28
- 125000000623 heterocyclic group Chemical group 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 10
- 230000013629 beta-amyloid clearance Effects 0.000 description 10
- 102000003802 alpha-Synuclein Human genes 0.000 description 6
- 108090000185 alpha-Synuclein Proteins 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 230000027928 long-term synaptic potentiation Effects 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019004203A JP6913698B2 (ja) | 2012-09-28 | 2019-01-15 | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707568P | 2012-09-28 | 2012-09-28 | |
| US61/707,568 | 2012-09-28 | ||
| US201361780171P | 2013-03-13 | 2013-03-13 | |
| US61/780,171 | 2013-03-13 | ||
| PCT/US2013/062413 WO2014052896A1 (en) | 2012-09-28 | 2013-09-27 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019004203A Division JP6913698B2 (ja) | 2012-09-28 | 2019-01-15 | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532289A JP2015532289A (ja) | 2015-11-09 |
| JP2015532289A5 true JP2015532289A5 (enExample) | 2016-10-20 |
| JP6523958B2 JP6523958B2 (ja) | 2019-06-05 |
Family
ID=50389029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534772A Expired - Fee Related JP6523958B2 (ja) | 2012-09-28 | 2013-09-27 | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
| JP2019004203A Expired - Fee Related JP6913698B2 (ja) | 2012-09-28 | 2019-01-15 | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019004203A Expired - Fee Related JP6913698B2 (ja) | 2012-09-28 | 2019-01-15 | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US9163055B2 (enExample) |
| EP (1) | EP2900680A4 (enExample) |
| JP (2) | JP6523958B2 (enExample) |
| AU (2) | AU2013323188B2 (enExample) |
| CA (1) | CA2885369A1 (enExample) |
| WO (1) | WO2014052896A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850367C (en) * | 2011-09-30 | 2021-06-01 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
| US9163055B2 (en) | 2012-09-28 | 2015-10-20 | Tufts University | Methods for treating glaucoma using uridine diphosphate derivatives |
| US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
| AU2015217221A1 (en) * | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| JP7121731B2 (ja) | 2016-09-26 | 2022-08-18 | タフツ・ユニバーシティ | ウリジンヌクレオシド誘導体、組成物及び使用方法 |
| TWI753037B (zh) | 2016-10-26 | 2022-01-21 | 美商星座製藥公司 | Lsd1抑制劑及其用途 |
| WO2018236221A2 (en) * | 2017-06-03 | 2018-12-27 | Can Holding B.V. | Neurodegenerative peptide deposit dissolution |
| KR102010558B1 (ko) * | 2017-12-08 | 2019-08-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
| WO2019112383A1 (ko) * | 2017-12-08 | 2019-06-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
| WO2020037275A1 (en) * | 2018-08-17 | 2020-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors |
| CN117700468B (zh) * | 2024-02-05 | 2024-05-03 | 深圳赛陆医疗科技有限公司 | 一种核苷酸类似物的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0621073B2 (ja) | 1986-03-06 | 1994-03-23 | 日水製薬株式会社 | 中枢抑制剤 |
| JP3032053B2 (ja) | 1991-09-06 | 2000-04-10 | 日水製薬株式会社 | ウリジン誘導体及びこれを含有する医薬 |
| EP0642789B1 (en) * | 1992-05-22 | 1999-09-29 | Senju Pharmaceutical Co., Ltd. | Remedy for glaucoma |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| EP1011688B1 (en) | 1997-08-29 | 2005-02-02 | The University of North Carolina at Chapel Hill | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| DK1140104T3 (da) | 1998-07-31 | 2008-01-21 | Massachusetts Inst Technology | Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo |
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US20060069061A1 (en) | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| EP1765075A4 (en) | 2004-06-10 | 2010-11-10 | Mclean Hospital Corp | PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS |
| US7851456B2 (en) | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| WO2008113072A2 (en) * | 2007-03-15 | 2008-09-18 | Board Of Regents, The University Of Texas System | Gpcr enhanced neuroprotection to treat brain injury |
| EP2136626A4 (en) * | 2007-03-19 | 2011-02-23 | Oregon State | Mannich base n-oxide drugs |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AU2009298802A1 (en) * | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| IT1398378B1 (it) * | 2010-02-22 | 2013-02-22 | Omikron Italia S R L | Citicolina per il trattamento del glaucoma e dell'ipertensione oculare. |
| US9221868B2 (en) | 2010-12-01 | 2015-12-29 | Bar-Ilan University | Uridine di- or tri-phosphate derivatives and uses thereof |
| CA2850367C (en) * | 2011-09-30 | 2021-06-01 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
| US9163055B2 (en) | 2012-09-28 | 2015-10-20 | Tufts University | Methods for treating glaucoma using uridine diphosphate derivatives |
| SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
| US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
-
2013
- 2013-09-27 US US14/039,748 patent/US9163055B2/en not_active Expired - Fee Related
- 2013-09-27 US US14/432,104 patent/US9913855B2/en not_active Expired - Fee Related
- 2013-09-27 EP EP13842176.3A patent/EP2900680A4/en not_active Withdrawn
- 2013-09-27 AU AU2013323188A patent/AU2013323188B2/en not_active Ceased
- 2013-09-27 CA CA2885369A patent/CA2885369A1/en not_active Abandoned
- 2013-09-27 WO PCT/US2013/062413 patent/WO2014052896A1/en not_active Ceased
- 2013-09-27 JP JP2015534772A patent/JP6523958B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-16 US US14/885,773 patent/US9750760B2/en not_active Expired - Fee Related
-
2018
- 2018-02-20 US US15/900,570 patent/US10632138B2/en not_active Expired - Fee Related
- 2018-04-05 AU AU2018202405A patent/AU2018202405A1/en not_active Abandoned
-
2019
- 2019-01-15 JP JP2019004203A patent/JP6913698B2/ja not_active Expired - Fee Related
-
2020
- 2020-04-15 US US16/849,946 patent/US11241450B2/en not_active Expired - Fee Related
-
2022
- 2022-01-31 US US17/589,864 patent/US20230012655A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532289A5 (enExample) | ||
| JP2016513668A5 (enExample) | ||
| JP2014528418A5 (enExample) | ||
| JP2023509375A5 (enExample) | ||
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| JP2021523200A5 (enExample) | ||
| RU2020107039A (ru) | Спироциклические соединения и способы их получения и применения | |
| JP2013502431A5 (enExample) | ||
| JP2014077003A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| JP2019520417A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| RU2017122824A (ru) | Пирролопиримидиновое соединение | |
| JP2021514001A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| JP2018035197A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2012524053A5 (enExample) | ||
| JP2015510941A5 (enExample) | ||
| JP2018529737A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2016506418A5 (enExample) |